Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody

Chuanli Zhao; Max Morgan; S. M.Mansour Haeryfar; Jonathan Blay; David W. Hoskin

doi:10.1007/s00262-002-0357-4

Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody

Chuanli Zhao, Max Morgan, S. M.Mansour Haeryfar, Jonathan Blay, David W. Hoskin

Psychology

科研成果: 期刊稿件 › 文章 › 同行评审

12 引用（Scopus）

源语言	英语
页（从-至）	185-193
页数	9
期刊	Cancer Immunology, Immunotherapy
卷	52
期	3
DOI	https://doi.org/10.1007/s00262-002-0357-4
出版状态	已出版 - 4月 1 2003

!!!ASJC Scopus Subject Areas

免疫学和过敏症
免疫学
肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s00262-002-0357-4

其它文件与链接

指纹

探究 'Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody' 的科研主题。它们共同构成独一无二的指纹。

引用此

Zhao, C., Morgan, M., Haeryfar, S. M. M., Blay, J., & Hoskin, D. W. (2003). Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunology, Immunotherapy, 52(3), 185-193. https://doi.org/10.1007/s00262-002-0357-4

Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. / Zhao, Chuanli; Morgan, Max; Haeryfar, S. M.Mansour 等.
在: Cancer Immunology, Immunotherapy, 卷 52, 号码 3, 01.04.2003, 页码 185-193.

科研成果: 期刊稿件 › 文章 › 同行评审

Zhao, C, Morgan, M, Haeryfar, SMM, Blay, J & Hoskin, DW 2003, 'Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody', Cancer Immunology, Immunotherapy, 卷 52, 号码 3, 页码 185-193. https://doi.org/10.1007/s00262-002-0357-4

@article{80e5c063055c489d86b66e6cab245ae0,

title = "Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody",

author = "Chuanli Zhao and Max Morgan and Haeryfar, {S. M.Mansour} and Jonathan Blay and Hoskin, {David W.}",

note = "Funding Information: Acknowledgements This work was supported by grants to D. Hoskin from the Natural Sciences and Engineering Research Council of Canada and the Canadian Breast Cancer Foundation, Atlantic Chapter. C. Zhou was supported by a scholarship from the China Scholarship Council. M. Morgan was the recipient of summer studentships from the Dalhousie Inflammation Group and the Cancer Biology Research Group of Dalhousie University. M. Haeryfar was supported by scholarships from the Natural Sciences and Engineering Research Council of Canada and the Killam Trust. The authors wish to thank Ms. A. Bennett for expert technical assistance.",

year = "2003",

month = apr,

day = "1",

doi = "10.1007/s00262-002-0357-4",

language = "English",

volume = "52",

pages = "185--193",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody

AU - Zhao, Chuanli

AU - Morgan, Max

AU - Haeryfar, S. M.Mansour

AU - Blay, Jonathan

AU - Hoskin, David W.

N1 - Funding Information: Acknowledgements This work was supported by grants to D. Hoskin from the Natural Sciences and Engineering Research Council of Canada and the Canadian Breast Cancer Foundation, Atlantic Chapter. C. Zhou was supported by a scholarship from the China Scholarship Council. M. Morgan was the recipient of summer studentships from the Dalhousie Inflammation Group and the Cancer Biology Research Group of Dalhousie University. M. Haeryfar was supported by scholarships from the Natural Sciences and Engineering Research Council of Canada and the Killam Trust. The authors wish to thank Ms. A. Bennett for expert technical assistance.

PY - 2003/4/1

Y1 - 2003/4/1

UR - http://www.scopus.com/inward/record.url?scp=0037385679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037385679&partnerID=8YFLogxK

U2 - 10.1007/s00262-002-0357-4

DO - 10.1007/s00262-002-0357-4

M3 - Article

C2 - 12649748

AN - SCOPUS:0037385679

SN - 0340-7004

VL - 52

SP - 185

EP - 193

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 3

ER -